metaPreg - Thiouracil, propylthiouracil, benzylthiouracil during pregnancy

Thiouracil, propylthiouracil, benzylthiouracil

Table Graphic exposition period:

Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)		0.99 [0.80, 1.24]	36%	10 studies	249,614	12,690	low
Major congenital malformations		0.69 [0.45, 1.06]	0%	5 studies	109	1,638	not evaluable
Genital anomalies		1.22 [0.96, 1.54]	0%	3 studies	25,811	11,037	not evaluable
Respiratory system anomalies		1.22 [0.76, 1.96]	33%	3 studies	16,007	11,037	not evaluable
Urinary malformations		1.63 [1.01, 2.62]	38%	3 studies	17,696	11,037	not evaluable
Eye defects		0.44 [0.06, 3.31]	0%	2 studies	2,484	1,107	not evaluable
Congenital heart defects		1.05 [0.84, 1.31]	17%	3 studies	77,568	11,037	not evaluable
Limb defects		1.20 [1.05, 1.37]	0%	3 studies	74,706	11,037	not evaluable
Severe congenital heart defect		1.20 [0.06, 22.67]	70%	2 studies	739	1,446	not evaluable
Abdominal wall defects		1.19 [0.15, 9.65]	0%	2 studies	926	1,107	not evaluable
Carbimazole embryopathy		1.61 [0.92, 2.79]	0%	3 studies	2,243	11,423	not evaluable
Digestive system anomalies		1.47 [0.59, 3.67]	40%	2 studies	12,045	10,148	not evaluable
Nervous system anomalies		1.09 [0.72, 1.65]	0%	2 studies	5,868	10,148	not evaluable
Syndromes and chromosomal abnormalities		0.84 [0.33, 2.12]	0%	2 studies	5,547	1,107	not evaluable
Ano-rectal atresia and stenosis		2.87 [0.24, 33.74]	67%	2 studies	1,055	1,413	not evaluable
Aortic valve atresia/stenosis		3.29 [0.12, 89.46]	70%	2 studies	494	1,412	not evaluable
Cardiac septal defects		-	-	0 study
Ear malformations		35.97 [1.72, 751.88]	-	1 study	2	218	not evaluable
Omphalocele		1.29 [0.13, 12.49]	0%	2 studies	154	1,446	not evaluable
Situs inversus		15.05 [1.80, 126.08]	0%	2 studies	27	1,446	not evaluable
Coarctation of aorta		7.97 [1.64, 38.62]	-	1 study	1,137	14	not evaluable
33 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
preterm (< 37 weeks)		1.03 [0.73, 1.46]	5%	5 studies	291	832	not evaluable
low birth weight (< 2500g)		1.41 [1.01, 1.97]	0%	2 studies	185	637	not evaluable
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Caesarean		1.09 [0.31, 3.78]	69%	2 studies	97	95	not evaluable
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Goiter		1.35 [0.37, 4.94]	0%	5 studies	8	167	not evaluable
Hypothyroidism (fetal/neonatal)		0.97 [0.18, 5.39]	0%	4 studies	3	180	not evaluable
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)		0.87 [0.12, 6.53]	0%	3 studies	2	81	not evaluable
Neonatal hyperthyrotropinemia		3.82 [0.36, 40.91]	57%	2 studies	15	86	not evaluable
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	Verdict	OR 95%CI	I2	k	No. cases	No. exposed	publication bias
Elective termination of pregnancy		1.32 [0.72, 2.42]	0%	3 studies	67	1,745	not evaluable
Early intrauterine death (< 22 weeks)		1.24 [0.62, 2.47]	58%	3 studies	394	1,745	not evaluable
Intrauterine deaths (as a whole)		1.23 [0.51, 2.93]	0%	3 studies	25	102	not evaluable
Perinatal death		2.00 [0.17, 23.33]	59%	2 studies	19	1,630	not evaluable
Late intrauterine deaths (> 22 weeks)		0.20 [0.01, 6.47]	74%	2 studies	9	167	not evaluable
Ectopic pregnancy		-	-	0 study